Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wright, Jennifer
REACT-AF, NCT05836987: The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation	Recruiting	3	5350	US	AFSW Guided DOAC, Apple Watch, Continuous DOAC therapy, Oral Anticoagulation therapy	Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI)	Atrial Fibrillation	07/29	07/29
VT3996-201, NCT03397706: Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies	Completed	1/2	64	US, RoW	VRx-3996, Nanatinostat, Valganciclovir	Viracta Therapeutics, Inc.	Epstein-Barr Virus Associated Lymphoma, Lymphoproliferative Disorders	04/23	05/23
NCT03982056 / 2007-007813-35 / ACTRN12612000071820: Float First: An Index of Floating: Factors Affecting Floating in Different Populations	Unknown status	N/A	178	Europe	this is an observational study there are no interventions	University of Portsmouth, Royal Darwin Hospital	Term birth, neonatal health	06/20	12/20
Mathews, Carolyn
No trials found